Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 7, 2025
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
GlobeNewswire
·
May 7, 2025
New York, NY, May 07, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new results with LX-101 in Thyroid Eye Disease …
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
GlobeNewswire
·
May 7, 2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference …
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 7, 2025
-- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired …
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on …
LifeStance Reports First Quarter 2025 Results
GlobeNewswire
·
May 7, 2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2025. (All …
Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025
GlobeNewswire
·
May 7, 2025
Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet AMD and DME Gräfelfing, Germany, May 7th, 2025 – Isarna Therapeutics presented final positive results from its …
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
GlobeNewswire
·
May 7, 2025
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the …
Oculis to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, …
Sanofi: A megelőzésbe való befektetés Európa egészségének és versenyképességének alapja
GlobeNewswire
·
May 7, 2025
VARSÓ, Lengyelország, May 07, 2025 (GLOBE NEWSWIRE) -- Az Európai Tanács jelenlegi elnökségét ellátó Lengyelország elnöki periódusa a végéhez közeleg, de az egészségpolitika Európa stratégiai napirendjének kiemelt helyén marad. A Katowice városában …
Sanofi: Investițiile în prevenție susțin sănătatea și competitivitatea Europei
GlobeNewswire
·
May 7, 2025
VARȘOVIA, Polonia, May 07, 2025 (GLOBE NEWSWIRE) -- Pe măsură ce președinția poloneză a Consiliului UE intră în ultima sa etapă, politica privind sănătatea rămâne în topul agendei strategice a Europei. La Congresul Economic European de la Katowice, discuț …
Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks! A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!
GlobeNewswire
·
May 7, 2025
St. Petersburg, Florida, May 07, 2025 (GLOBE NEWSWIRE) -- as per studies a person's complete health depends on gut and skin health, especially in our fast-paced environment. People are most concerned about their stomach and skin issues, which can lead to …
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
GlobeNewswire
·
May 7, 2025
Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence In vivo demonstration of ammonia …
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
GlobeNewswire
·
May 7, 2025
Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol plus 6-month follow up Study sites in North America, Africa and Europe First clinical …
PrimeBiome Reviews Consumer Reports: Critical Complaints & Customer Reviews Exposed!
GlobeNewswire
·
May 7, 2025
ANCHORAGE, Alaska, May 07, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is a natural skin and gut health formula that has been gaining immense popularity in the market. As per the claims of the manufacturers, this formula is created using scientifically proven …
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
GlobeNewswire
·
May 7, 2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, …
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
GlobeNewswire
·
May 7, 2025
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following …